{"ATC Code":"A02BC02","Abbreviation":"","Aliases":["Pantozol","Pantoprazol","Pantoprazolum","Altopan","Panyocid","Zovanta","apo-Pantoprazole","Pantecta Control","SK-96022","1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-"],"Biological Half-Life":"About 1 hour","Boiling Point":"586.9±60.0 °C at 760 mmHg","CAS":"102625-70-7","ChEBI":"CHEBI:7915","ChEMBL":"CHEMBL1502","ChemicalClasses":["benzimidazole"],"Chirality":"racemic","Classes":null,"Color/Form":"Off-white solid","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Ulcer Agents; Gastrointestinal Agents; Proton Pump Inhibitors","Drug Indication":"**Pantoprazole Injection**:  **Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis**  Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.  **Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome**  Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.  **Pantoprazole delayed-release oral suspension**:  **Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)**  Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.  **Maintenance of healing of erosive esophagitis**  Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.  **Pathological hypersecretory conditions including Zollinger-Ellison syndrome**  Indicated for the long-term treatment of the above conditions.","Drug Warnings":"Anaphylaxis has been reported with the use of IV pantoprazole sodium. Immediate medical intervention and drug discontinuance are required if anaphylaxis or other severe hypersensitivity reactions occurs. /Pantoprazole sodium/","DrugClasses":["hormone"],"DurationOfAction":"","EliminationHalfLife":"1 – 2 hours","Erowid Experience Reports":[],"European Community (EC) Number":"600-331-6","FDA Pharmacological Classification":"D8TST4O562","FullSalts":["Sodium pantoprazole"],"HMDB ID":"HMDB0005017","HeavyAtomCount":26,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Ulcer Agents; Gastrointestinal Agents; Proton Pump Inhibitors","IUPACName":"6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole","InChI":"InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)","InChIKey":"IQPSEEYGBUAQFF-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)","Melting Point":"149-150","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e15\u003c/sub\u003eF\u003csub\u003e2\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e4\u003c/sub\u003eS","MolecularWeight":"383.4 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"This drug acts to decrease gastric acid secretion, which reduces stomach acidity. Pantoprazole administration leads to long-lasting inhibition of gastric acid secretion.  **General Effects**  Pantoprazole has been shown to reduce acid reflux-related symptoms, heal inflammation of the esophagus, and improve patient quality of life more effectively than histamine-2 receptor antagonists (H2 blockers). This drug has an excellent safety profile and a low incidence of drug interactions. It can be used safely in various high-risk patient populations, including the elderly and those with renal failure or moderate hepatic dysfunction.  Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.  PPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.   **A note on laboratory testing abnormalities**  During treatment with antisecretory medicinal products such as pantoprazole, serum gastrin (a peptide hormone that stimulates secretion of gastric acid) increases in response to the decreased acid secretion caused by proton pump inhibition. The increased gastrin level may interfere with investigations for neuroendocrine tumors. Published evidence suggests that proton pump inhibitors should be stopped 14 days before chromogranin A (CgA) measurements. This permits chromogranin A levels, that might be falsely elevated after proton pump inhibitor treatment, to return to the normal reference range.   Reports have been made of false-positive results in urine screening tests for tetrahydrocannabinol (THC) in patients receiving the majority of proton pump inhibitors, including pantoprazole. A confirmatory method should be used.","Physical Description":"Solid","PrevSalts":["sodium"],"PubChemId":4679,"Record Description":["Pantoprazole is a member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. It has a role as an anti-ulcer drug, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, a xenobiotic and an environmental contaminant. It is a member of benzimidazoles, a member of pyridines, an aromatic ether, an organofluorine compound and a sulfoxide. It is a conjugate acid of a pantoprazole(1-).","Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of H. pylori infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole].  Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists longer than 24 hours.  Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal C. difficile), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.  PPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.  Pantoprazole doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase in hypersecretion.","Pantoprazole is a Proton Pump Inhibitor. The mechanism of action of pantoprazole is as a Proton Pump Inhibitor.","Pantoprazole is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease. Pantoprazole therapy is associated with a low rate of transient and asymptomatic serum aminotransferase elevations and is a rare cause of clinically apparent liver injury.","Pantoprazole is a substituted benzimidazole and proton pump inhibitor with antacid activity. Pantoprazole is a lipophilic weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulphenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.","PANTOPRAZOLE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 26 investigational indications.","2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.","See also: Pantoprazole Sodium (has salt form); Pantoprazole magnesium (is active moiety of).","Pantoprazole is a member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. It has a role as an anti-ulcer drug, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, a xenobiotic and an environmental contaminant. It is a member of benzimidazoles, a member of pyridines, an aromatic ether, an organofluorine compound and a sulfoxide. It is a conjugate acid of a pantoprazole(1-).","LiverTox|Gastroinestinal|Acid peptic disease|PPI"],"RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Pantoprazole","Name":"Pantoprazole","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q286846","Name":"Pantoprazole","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00213","Name":"Pantoprazole","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4679","Name":"Pantoprazole","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/11181988","Name":"(+)-Pantoprazole","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1502","Name":"Pantoprazole","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2096747","Name":"(+)-Pantoprazole","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7915","Name":"Pantoprazole","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=102625-70-7","Name":"Pantoprazole","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=142706-18-1","Name":"(+)-Pantoprazole","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005017","Name":"Pantoprazole","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C11806","Name":"Pantoprazole","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/D8TST4O562","Name":"Pantoprazole","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/8UUN42B3QT","Name":"(+)-Pantoprazole","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4023416","Name":"Pantoprazole","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4679, Pantoprazole. Accessed June 27, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4679\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4679\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Pantoprazole. UNII: D8TST4O562. Global Substance Registration System. Accessed June 27, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/D8TST4O562\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/D8TST4O562\u003c/a\u003e","Pantoprazole 20mg gastro-resistant tablets - Summary of Product Characteristics (SmPC). November 25, 2019. Accessed June 27, 2025. \u003ca href=https://www.medicines.org.uk/emc/product/450/smpc\u003ehttps://www.medicines.org.uk/emc/product/450/smpc\u003c/a\u003e"],"SMILES":"COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC","Salts":["sodium"],"SaltsAcidCount":[2],"SaltsAmineCount":[2],"SaltsUNII":["6871619Q5X"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"United Kingdom","ref":["3"],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"Freely soluble in water.","StereoisomerRacemic":"(RS)-Pantoprazole","Stereoisomers":["(+)-Pantoprazole"],"StereoisomersUNII":["8UUN42B3QT"],"StoreUNII":["D8TST4O562"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="56.846mm" version="1.2" viewBox="0 0 176.148 56.846" width="176.148mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="57.0" stroke="none" width="177.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="175.238" x2="163.657" y1="14.247" y2="14.246"/>
                  
            <line class="bond" id="mol1bnd2" x1="158.028" x2="152.376" y1="17.656" y2="27.442"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="152.376" x2="137.127" y1="27.442" y2="27.435"/>
                        
                <line x1="150.968" x2="138.535" y1="29.88" y2="29.874"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="137.127" x2="129.505" y1="27.435" y2="40.632"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="129.505" x2="135.017" y1="40.632" y2="50.174"/>
                        
                <line x1="132.321" x2="137.128" y1="40.632" y2="48.954"/>
                      
                <line class="hi" stroke="#3050F8" x1="135.017" x2="132.261" y1="50.174" y2="45.403"/>
                <line class="hi" stroke="#3050F8" x1="137.128" x2="134.72449999999998" y1="48.954" y2="44.793"/>
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="140.473" x2="152.38" y1="53.838" y2="53.843"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="152.38" x2="160.002" y1="53.843" y2="40.646"/>
                        
                <line x1="150.973" x2="157.186" y1="51.404" y2="40.646"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="152.376" x2="160.002" y1="27.442" y2="40.646"/>
                  
            <line class="bond" id="mol1bnd9" x1="129.505" x2="114.265" y1="40.632" y2="40.632"/>
                  
            <line class="bond" id="mol1bnd10" x1="114.265" x2="108.535" y1="40.632" y2="30.707"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="107.614" x2="111.24" y1="23.318" y2="17.037"/>
                        
                <line x1="109.725" x2="113.351" y1="24.537" y2="18.256"/>
                      
                <line class="hi" stroke="#C6C62C" x1="107.614" x2="109.42699999999999" y1="23.318" y2="20.177500000000002"/>
                <line class="hi" stroke="#FF0D0D" x1="111.24" x2="109.42699999999999" y1="17.037" y2="20.177500000000002"/>
                <line class="hi" stroke="#C6C62C" x1="109.725" x2="111.538" y1="24.537" y2="21.3965"/>
                <line class="hi" stroke="#FF0D0D" x1="113.351" x2="111.538" y1="18.256" y2="21.3965"/>
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="103.73" x2="91.405" y1="27.433" y2="27.433"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="85.07" x2="91.405" y1="36.145" y2="27.433"/>
                        
                <line x1="83.098" x2="88.39" y1="34.711" y2="27.433"/>
                      
                <line class="hi" stroke="#3050F8" x1="85.07" x2="88.2375" y1="36.145" y2="31.789"/>
                <line class="hi" stroke="#3050F8" x1="83.098" x2="85.744" y1="34.711" y2="31.072"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="79.191" x2="67.936" y1="38.674" y2="35.053"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="67.936" x2="67.936" y1="35.053" y2="19.813"/>
                        
                <line x1="65.497" x2="65.497" y1="33.645" y2="21.222"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="67.936" x2="79.191" y1="19.813" y2="16.193"/>
                  
            <line class="bond" id="mol1bnd17" x1="91.405" x2="85.07" y1="27.433" y2="18.722"/>
                  
            <line class="bond" id="mol1bnd18" x1="67.936" x2="54.728" y1="19.813" y2="12.193"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="54.728" x2="41.52" y1="12.193" y2="19.813"/>
                        
                <line x1="54.728" x2="43.958" y1="15.009" y2="21.222"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="41.52" x2="41.52" y1="19.813" y2="35.053"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="41.52" x2="54.728" y1="35.053" y2="42.673"/>
                        
                <line x1="43.958" x2="54.728" y1="33.645" y2="39.858"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="67.936" x2="54.728" y1="35.053" y2="42.673"/>
                  
            <line class="bond" id="mol1bnd23" x1="41.52" x2="31.598" y1="19.813" y2="14.083"/>
                  
            <line class="bond" id="mol1bnd24" x1="25.042" x2="15.123" y1="14.085" y2="19.809"/>
                  
            <line class="bond" id="mol1bnd25" x1="15.123" x2="4.167" y1="19.809" y2="13.481"/>
                  
            <line class="bond" id="mol1bnd26" x1="15.123" x2="15.121" y1="19.809" y2="31.199"/>
                  
            <line class="bond" id="mol1bnd27" x1="137.127" x2="131.477" y1="27.435" y2="17.641"/>
                  
            <line class="bond" id="mol1bnd28" x1="131.481" x2="137.136" y1="10.826" y2="1.038"/>
                  
            <path class="atom" d="M162.257 14.242q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM158.394 14.242q-.0 .923 .387 1.459q.392 .529 1.22 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.834 -.0 -1.226 .523q-.393 .524 -.393 1.453z" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M139.072 56.286h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M108.19 28.57q.0 .649 -.476 1.018q-.47 .364 -1.268 .364q-.417 -.0 -.768 -.066q-.345 -.059 -.578 -.173v-.589q.245 .113 .608 .203q.369 .089 .762 .089q.547 -.0 .827 -.214q.28 -.215 .28 -.578q-.0 -.238 -.107 -.399q-.101 -.166 -.351 -.309q-.25 -.143 -.697 -.298q-.625 -.226 -.946 -.554q-.316 -.333 -.316 -.899q-.0 -.392 .196 -.666q.203 -.28 .554 -.429q.357 -.155 .816 -.155q.404 .0 .738 .078q.339 .071 .613 .196l-.196 .53q-.25 -.113 -.548 -.185q-.298 -.077 -.625 -.077q-.459 .0 -.691 .196q-.232 .197 -.232 .518q.0 .244 .101 .411q.107 .167 .34 .298q.232 .125 .631 .28q.428 .154 .726 .339q.298 .179 .452 .435q.155 .25 .155 .636z" fill="#C6C62C" id="mol1atm10" stroke="none"/>
                  
            <path class="atom" d="M116.525 14.232q-.0 .756 -.256 1.328q-.256 .565 -.757 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.501 .309 .757 .875q.256 .565 .256 1.327zM112.661 14.232q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M84.405 42.177h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" fill="#3050F8" id="mol1atm13" stroke="none"/>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M84.405 17.59h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.029q-.006 -.107 -.017 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M84.268 12.128h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M30.582 12.188q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.245 -.572 -.245 -1.334q.0 -.75 .245 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM26.718 12.188q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .524 -.393 1.452z" id="mol1atm21" stroke="none"/>
                  
            <path class="atom" d="M1.173 14.637h-.613v-4.9h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.078z" fill="#90E050" id="mol1atm23" stroke="none"/>
                  
            <path class="atom" d="M14.368 37.499h-.613v-4.899h2.732v.541h-2.119v1.739h1.994v.541h-1.994v2.078z" fill="#90E050" id="mol1atm24" stroke="none"/>
                  
            <path class="atom" d="M131.771 14.231q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.245 -.572 -.245 -1.334q.0 -.75 .245 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM127.907 14.231q.0 .923 .387 1.459q.393 .529 1.221 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.834 -.0 -1.227 .523q-.393 .524 -.393 1.453z" id="mol1atm25" stroke="none"/>
                
            <line class="hi" id="mol1bnd1" stroke="#FF0D0D" x1="163.657" x2="169.4475" y1="14.246" y2="14.246500000000001"/>
            <line class="hi" id="mol1bnd2" stroke="#FF0D0D" x1="158.028" x2="155.202" y1="17.656" y2="22.549"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="140.473" x2="146.4265" y1="53.838" y2="53.840500000000006"/>
            <line class="hi" id="mol1bnd10" stroke="#C6C62C" x1="108.535" x2="111.4" y1="30.707" y2="35.6695"/>
            <line class="hi" id="mol1bnd12" stroke="#C6C62C" x1="103.73" x2="97.5675" y1="27.433" y2="27.433"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="79.191" x2="73.5635" y1="38.674" y2="36.8635"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="79.191" x2="73.5635" y1="16.193" y2="18.003"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="79.191" x2="73.5635" y1="16.193" y2="18.003"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="85.07" x2="88.2375" y1="18.722" y2="23.0775"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="85.07" x2="88.2375" y1="18.722" y2="23.0775"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="31.598" x2="36.559" y1="14.083" y2="16.948"/>
            <line class="hi" id="mol1bnd24" stroke="#FF0D0D" x1="25.042" x2="20.0825" y1="14.085" y2="16.947000000000003"/>
            <line class="hi" id="mol1bnd25" stroke="#90E050" x1="4.167" x2="9.645" y1="13.481" y2="16.645"/>
            <line class="hi" id="mol1bnd26" stroke="#90E050" x1="15.121" x2="15.122" y1="31.199" y2="25.504"/>
            <line class="hi" id="mol1bnd27" stroke="#FF0D0D" x1="131.477" x2="134.30200000000002" y1="17.641" y2="22.537999999999997"/>
            <line class="hi" id="mol1bnd28" stroke="#FF0D0D" x1="131.481" x2="134.30849999999998" y1="10.826" y2="5.932"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Therapeutic Uses":"Pantoprazole delayed-release tablets are indicated for the short-term (up to 8 weeks) treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD). Pantoprazole for injection is indicated for the short-term (7 to 10 days) treatment of GERD in patients who are unable to continue taking pantoprazole delayed-release tablets. Pantoprazole for injection is not indicated for initial treatment of GERD. /Included in US product labeling/ /Pantoprazole sodium/","Title":"Pantoprazole","UNII":"D8TST4O562","Wikidata":"Q286846","Wikipedia":"Pantoprazole","XLogP":2.4}